Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Dedman

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Pulmonary Therapy|February 7, 2020
Treatment Patterns of New Users of Fluticasone Furoate/Vilanterol in Asthma and COPD in UK Primary Care: Retrospective Cohort StudyDaniel Dedman, Sonia J Coton, Rebecca E Ghosh, et al.
Annals of Epidemiology|June 25, 2013
Lower respiratory tract infection in the first year of life is associated with worse lung function in adult life: prospective results from the Barry Caerphilly Growth studyJames A Lopez Bernal, Mark N Upton, A John Henderson, et al.
European Urology|December 15, 2007
Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT studyDerek J Rosario, J Athene Lane, Chris Metcalfe, et al.
BJU International|September 19, 2006
Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UKLucy A Brindle, Steven E Oliver, Daniel Dedman, et al.
Pharmacoepidemiology and Drug Safety|April 18, 2019
Limitations for health research with restricted data collection from UK primary careHelen Strongman, Rachael Williams, Wilhelmine Meeraus, et al.
BJU International|July 15, 2016
Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of lifeAthene Lane, Chris Metcalfe, Grace J Young, et al.
The Lancet. Oncology|August 29, 2014
Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trialJ Athene Lane, Jenny L Donovan, Michael Davis, et al.
Health Technology Assessment (Winchester, England)|March 19, 2021
Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort studyDanielle E Robinson, M Sanni Ali, Victoria Y Strauss, et al.
Clinical Epidemiology|May 21, 2020
Evaluating the Effectiveness of an Additional Risk Minimization Measure to Reduce the Risk of Prescribing Mirabegron to Patients with Severe Uncontrolled Hypertension in Four European CountriesEdith M Heintjes, Irene D Bezemer, Daniel Prieto-Alhambra, et al.
Clinical Epidemiology|March 22, 2018
A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study)Jordi Castellsague, Josephina G Kuiper, Anton Pottegård, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Pulmonary Therapy|February 7, 2020
Treatment Patterns of New Users of Fluticasone Furoate/Vilanterol in Asthma and COPD in UK Primary Care: Retrospective Cohort StudyDaniel Dedman, Sonia J Coton, Rebecca E Ghosh, et al.
Annals of Epidemiology|June 25, 2013
Lower respiratory tract infection in the first year of life is associated with worse lung function in adult life: prospective results from the Barry Caerphilly Growth studyJames A Lopez Bernal, Mark N Upton, A John Henderson, et al.
European Urology|December 15, 2007
Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT studyDerek J Rosario, J Athene Lane, Chris Metcalfe, et al.
BJU International|September 19, 2006
Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UKLucy A Brindle, Steven E Oliver, Daniel Dedman, et al.
Pharmacoepidemiology and Drug Safety|April 18, 2019
Limitations for health research with restricted data collection from UK primary careHelen Strongman, Rachael Williams, Wilhelmine Meeraus, et al.
BJU International|July 15, 2016
Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of lifeAthene Lane, Chris Metcalfe, Grace J Young, et al.
The Lancet. Oncology|August 29, 2014
Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trialJ Athene Lane, Jenny L Donovan, Michael Davis, et al.
Health Technology Assessment (Winchester, England)|March 19, 2021
Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort studyDanielle E Robinson, M Sanni Ali, Victoria Y Strauss, et al.
Clinical Epidemiology|May 21, 2020
Evaluating the Effectiveness of an Additional Risk Minimization Measure to Reduce the Risk of Prescribing Mirabegron to Patients with Severe Uncontrolled Hypertension in Four European CountriesEdith M Heintjes, Irene D Bezemer, Daniel Prieto-Alhambra, et al.
Clinical Epidemiology|March 22, 2018
A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study)Jordi Castellsague, Josephina G Kuiper, Anton Pottegård, et al.
Pageof 3